Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Cluster analysis and display of genome-wide expression patterns

Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974

Tissue microarrays for high-throughput molecular profiling of tumor specimens

Kononen, J., Bubendorf, L., Kallionimeni, A., Barlund, M. T., Schraml, P., Leighton, S. B., Torhorst, J. K. H., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,101

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

Epidermal growth factor-related peptides and their receptors in human malignancies

Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,695

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605

Epithelial-Mesenchymal Transitions in Development and Disease

Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545

Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening

Gupta, P. B., Önder, T. T., Jiang, G., Tao, K. X., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009) · Cell · doi:10.1016/j.cell.2009.06.034 · Cited by 2,429

Lung Cancer

Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802714 · Cited by 2,435

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

Arumugam, T., Ramachandran, V., Fournier, K. F., Wang, H., Marquis, L., Abbruzzese, J. L., Gallick, G. E., Logsdon, C. D., McConkey, D. J., & Choi, W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2819 · Cited by 866

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations

LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 809

The great escape: tumour cell plasticity in resistance to targeted therapy

Boumahdi, S., & de Sauvage, F. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 785

Involvement of Members of the Cadherin Superfamily in CancerPreprint

Berx, G., & Roy, F. M. V. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003129 · Cited by 706

Epithelial–mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic

Voulgari, A., & Pintzas, A. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.03.002 · Cited by 683

Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

Armstrong, A. J., Marengo, M. S., Oltean, S., Kemeny, G., Bitting, R. L., Turnbull, J. D., Herold, C. I., Marcom, P. K., George, D. J., & García-Blanco, M. A. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0490 · Cited by 646

Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression

Lo, H., Hsu, S.-C., Xia, W., Cao, X., Shih, J., Wei, Y., Abbruzzese, J. L., Hortobágyi, G. N., & Hung, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0575 · Cited by 647

Molecular analysis of circulating tumour cells—biology and biomarkers

Krebs, M., Metcalf, R. L., Carter, L., Brady, G., Blackhall, F. H., & Dive, C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.253 · Cited by 638

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL

Wagner, K. W., Punnoose, E. A., Januario, T., Lawrence, D. A., Pitti, R. M., Lancaster, K., Lee, D., von Goetz, M., Yee, S. F., Tótpál, K., et al. (2007) · Nature Medicine · doi:10.1038/nm1627 · Cited by 607

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

Roock, W. D., de Vriendt, V., Normanno, N., Ciardiello, F., & Tejpar, S. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70209-6 · Cited by 626

EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness

Sànchez‐Tilló, E., Liu, Y., de Barrios, O., Siles, L., Fanlo, L., Cuatrecasas, M., Darling, D. S., Dean, D. C., Castells, A., & Postigo, A. A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1122-2 · Cited by 545

TGF-β Signaling in Lung Health and Disease

Saito, A., Horie, M., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082460 · Cited by 515

Mechanisms of resistance to EGFR-targeted drugs: lung cancer

Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000060 · Cited by 476

Mechanism of the Mesenchymal–Epithelial Transition and Its Relationship with Metastatic Tumor Formation

Yao, D., Dai, C., & Peng, S. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0568 · Cited by 469

Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib

Carey, K. D., Garton, A. J., Romero, M. S., Kahler, J., Thomson, S., Ross, S., Park, F., Haley, J. D., Gibson, N., & Sliwkowski, M. X. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0453 · Cited by 445

The tumor microenvironment is a dominant force in multidrug resistance

Correia, A. L., & Bissell, M. J. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.006 · Cited by 455

Cancer stem cells and chemoresistance: The smartest survives the raid

Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 446

miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy

Adam, L., Zhong, M., Choi, W., Wei, Q., Nicoloso, M. S., Arora, A., Calin, G. A., Wang, H., Siefker-Radtke, A. O., McConkey, D. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2245 · Cited by 410

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors

Daemen, A., Peterson, D., Sahu, N., McCord, R., Du, X., Liu, B., Kowanetz, K., Hong, R., Moffat, J., Gao, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501605112 · Cited by 398

TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009472107 · Cited by 389

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

Ciuleanu, T., Stelmakh, L., Cicenas, S., Miliauskas, S., Grigorescu, A. C., Hillenbach, C., Johannsdottir, H. K., Klughammer, B., & Gonzalez, E. E. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70385-0 · Cited by 374

Epithelial–mesenchymal transition and tumour invasion

Guarino, M. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.07.011 · Cited by 375

Early events in cell adhesion and polarity during epithelial-mesenchymal transition

Huang, R. Y., Guilford, P., & Thiery, J. P. (2012) · Journal of Cell Science · doi:10.1242/jcs.099697 · Cited by 407

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

Ladanyi, M., & Pao, W. J. (2008) · Modern Pathology · doi:10.1038/modpathol.3801018 · Cited by 374

Characterizing deformability and surface friction of cancer cells

Byun, S., Son, S., Amodei, D., Cermak, N., Bagnall, J., Kang, J. H., Hecht, V. C., Winslow, M. M., Jacks, T., Mallick, P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218806110 · Cited by 370

EMT‐associated microRNAs and their roles in cancer stemness and drug resistance

Pan, G., Liu, Y., Shang, L., Zhou, F., & Yang, S. (2021) · 癌症：英文版 · doi:10.1002/cac2.12138 · Cited by 362

The Epithelial-to-Mesenchymal Transition and Cancer Stem Cells: A Coalition Against Cancer Therapies

Hollier, B. G., Evans, K., & Mani, S. A. (2009) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-009-9110-3 · Cited by 359

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

Corkery, B., Crown, J. P., CLYNES, M. M., & O’Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348

Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance

Wang, Z. P., Li, Y., Ahmad, A., Azmi, A. S., Kong, D., Banerjee, S., & Sarkar, F. H. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.07.001 · Cited by 348

Epithelial–mesenchymal transition: a new target in anticancer drug discovery

Marcucci, F., Stassi, G., & Maria, R. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.13 · Cited by 345

Mesenchymal–epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer

Gunasinghe, N. P. A. D., Wells, A. H., Thompson, E. W., & Hugo, H. J. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9377-5 · Cited by 339

Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas

Jolly, M. K., Somarelli, J. A., Sheth, M. U., Biddle, A., Tripathi, S. C., Armstrong, A. J., Hanash, S., Bapat, S. A., Rangarajan, A., & Levine, H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.007 · Cited by 337

Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers

Sabbah, M., Emami, S., Redeuilh, G., Julien-Grille, S., Prevost, G. P., Zimber, A., Ouelaa-Benslama, R., Bracke, M., Wever, O. D., & Gespach, C. P. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.07.001 · Cited by 325

Epithelial-to-Mesenchymal Transition Activates PERK–eIF2α and Sensitizes Cells to Endoplasmic Reticulum Stress

Feng, Y., Sokol, E. S., Fitz, C. D. V., Sanduja, S., Claessen, J. H. L., Proia, T. A., Jin, D. X., Reinhardt, F., Ploegh, H. L., Wang, Q., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0945 · Cited by 329

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer

Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319

The EMT regulator slug and lung carcinogenesis

Shih, J.-Y., & Yang, P. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr110 · Cited by 315

Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells

Fuchs, B. C., Fujii, T., Dorfman, J. D., Goodwin, J. M., Zhu, A. X., Lanuti, M. D., & Tanabe, K. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2460 · Cited by 308

Loss of miR-200c Expression Induces an Aggressive, Invasive, and Chemoresistant Phenotype in Non–Small Cell Lung Cancer

Ceppi, P., Mudduluru, G., Kumarswamy, R., Rapa, I., Scagliotti, G. V., Papotti, M. G., & Allgayer, H. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0052 · Cited by 304

Cyclooxygenase-2–Dependent Regulation of E-Cadherin: Prostaglandin E2 Induces Transcriptional Repressors ZEB1 and Snail in Non–Small Cell Lung Cancer

Dohadwala, M., Yang, S.-C., Luo, J., Sharma, S. P., Batra, R. K., Huang, M., Lin, Y., Goodglick, L., Krysan, K., Fishbein, M. C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3635 · Cited by 283

Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer

Brugger, W., Triller, N., Błasińska-Morawiec, M., Curescu, S., Sakalauskas, R., Manikhas, G. M., Mazières, J., Whittom, R., Ward, C., Mayne, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8162 · Cited by 284

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib

Suda, K., Tomizawa, K., Fujii, M., Murakami, H., Osada, H., Maehara, Y., Yatabe, Y., Sekido, Y., & Mitsudomi, T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318216ee52 · Cited by 283

Emerging role of tumor cell plasticity in modifying therapeutic response

Qin, S., Jiang, J., Lü, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 289

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma

Frederick, B. A., Helfrich, B. A., Coldren, C. D., Zheng, D., Chan, D., Bunn, P. A., & Raben, D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0138 · Cited by 270

EMT : Present and future in clinical oncology

Santamarı́a, P. G., Moreno‐Bueno, G., Portillo, F., & Cano, A. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12091 · Cited by 263

Collagen I Promotes Epithelial-to-Mesenchymal Transition in Lung Cancer Cells via Transforming Growth Factor–β Signaling

Shintani, Y., Maeda, M., Chaika, N. V., Johnson, K. R., & Wheelock, M. J. (2007) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0071oc · Cited by 259

A Convergence-Based Framework for Cancer Drug Resistance

Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258

Mechanisms of disease: epithelial-mesenchymal transition - does cellular plasticity fuel neoplastic progression?

Turley, E. A., Veiseh, M., Radisky, D. C., & Bissell, M. J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1089 · Cited by 253

Gene Expression Profiles Identify Epithelial-to-Mesenchymal Transition and Activation of Nuclear Factor-κB Signaling as Characteristics of a High-risk Head and Neck Squamous Cell Carcinoma

Chung, C. H., Parker, J. S., Ely, K., Carter, J., Yi, Y., Murphy, B. A., Ang, K. K., El‐Naggar, A. K., Zanation, A. M., Cmelak, A. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1213 · Cited by 254

Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives

Saunders, N. A., Simpson, F., Thompson, E. W., Hill, M. M. C., Endo‐Munoz, L., Leggatt, G. R., Minchin, R. F., & Guminski, A. D. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101131 · Cited by 252

Molecular Biology of Lung Cancer: Clinical Implications

Larsen, J. E., & Minna, J. D. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.08.003 · Cited by 251

Targeting Notch signaling pathway to overcome drug resistance for cancer therapy

Wang, Z. P., Li, Y., Ahmad, A., Azmi, A. S., Banerjee, S., Kong, D., & Sarkar, F. H. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.06.001 · Cited by 233

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies

Ye, X., Li, Y., Stawicki, S. S., Couto, S. S., Eastham‐Anderson, J., Kallop, D. Y., Weimer, R. M., Wu, Y., & Pei, L. (2010) · Oncogene · doi:10.1038/onc.2010.268 · Cited by 231

Cancer drug resistance induced by EMT: novel therapeutic strategies

Rivas, J. D. L., Brozović, A., Izraely, S., Casas-Pais, A., Witz, I. P., & Figueroa, A. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03063-7 · Cited by 236

Molecular and pathological signatures of epithelial–mesenchymal transitions at the cancer invasion front

Wever, O. D., Pauwels, P., Craene, B. D., Sabbah, M., Emami, S., Redeuilh, G., Gespach, C. P., Bracke, M., & Berx, G. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0464-1 · Cited by 233

Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression

McConkey, D. J., Lee, S., Choi, W., Tran, M., Majewski, T., Lee, S., Siefker-Radtke, A. O., Dinney, C. P., & Czerniak, B. A. (2010) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.04.008 · Cited by 227

Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line

Rho, J. K., Choi, Y. J., Lee, J. K., Ryoo, B., Na, I. I., Yang, S. H., Kim, C. H., & Lee, J. C. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.05.017 · Cited by 220

Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy

Kemper, K., de Goeje, P. L., Peeper, D. S., & van Amerongen, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1174 · Cited by 216

EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer

Tulchinsky, E. M., Demidov, O. N., Kriajevska, M. V., Barlev, N. A., & Имянитов, Е. Н. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.10.003 · Cited by 214

Molecular biology of lung cancer: Clinical implications

Fong, K. M., & Minna, J. D. (2002) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(03)00062-5 · Cited by 211

Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression

Wendt, M. K., Tian, M., & Schiemann, W. P. (2011) · Cell and Tissue Research · doi:10.1007/s00441-011-1199-1 · Cited by 215

Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors

Buck, E. A., Eyzaguirre, A., Rosenfeld-Franklin, M., Thomson, S., Mulvihill, M. J., Barr, S. M., Brown, E., O’Connor, M., Yao, Y., Pachter, J. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6720 · Cited by 211

A systems view of epithelial–mesenchymal transition signaling states

Thomson, S., Petti, F., Sujka-Kwok, I., Mercado, P., Bean, J. M., Monaghan, M., Seymour, S. L., Argast, G. M., Epstein, D. M., & Haley, J. D. (2010) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9367-3 · Cited by 216

Drug resistance to targeted therapies: Déjà vu all over again

Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 222

Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Sang, J., Acquaviva, J., Friedland, J. C., Smith, D. L., Sequeira, M., Zhang, C., Jiang, Q., Xue, L., Lovly, C. M., Jimenez, J.-P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0440 · Cited by 209

miR-200bc/429 cluster targets PLCγ1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer

Uhlmann, S., Zhang, J., Schwäger, A., Mannsperger, H., Riazalhosseini, Y., Burmester, S., Ward, A., Korf, U., Wiemann, S., & Şahin, Ö. (2010) · Oncogene · doi:10.1038/onc.2010.201 · Cited by 199

Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells

Heery, R., Finn, S. P., Cuffe, S. D., & Gray, S. G. (2017) · Cancers · doi:10.3390/cancers9040038 · Cited by 200

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.

Lin, Y., Wang, X., & Jin, H. (2014) · Europe PMC (PubMed Central) · Cited by 198

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

Barr, S. M., Thomson, S., Buck, E. A., Russo, S. M., Petti, F., Sujka-Kwok, I., Eyzaguirre, A., Rosenfeld-Franklin, M., Gibson, N. W., Miglarese, M. R., et al. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9121-7 · Cited by 199

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

Witta, S. E., Jotte, R. M., Konduri, K., Neubauer, M., Spira, A. I., Ruxer, R. L., Varella‐Garcia, M., Bunn, P. A., & Hirsch, F. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9411 · Cited by 198

Differences in Survival Among Patients With Sarcomatoid Carcinoma, Carcinosarcoma and Urothelial Carcinoma of the Bladder

Wright, J. L., Black, P. C., Brown, G. A., Porter, M. P., Kamat, A. M., Dinney, C. P., & Lin, D. W. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.08.038 · Cited by 195

Epithelial mesenchymal transition and lung cancer.

Xiao, D., & He, J. (2010) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.02.03.7 · Cited by 193

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

Buck, E. A., Eyzaguirre, A., Barr, S. M., Thompson, S. D., Sennello, R., Young, D., Iwata, K. K., Gibson, N. W., Cagnoni, P. J., & Haley, J. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0462 · Cited by 193

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

Thomson, S., Petti, F., Sujka-Kwok, I., Epstein, D. M., & Haley, J. D. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9200-4 · Cited by 190

MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells

Kitamura, K., Seike, M., Okano, T., Matsuda, K., Miyanaga, A., Mizutani, H., Noro, R., Minegishi, Y., Kubota, K., & Gemma, A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0448 · Cited by 190

Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

Chung, J.-H., Rho, J. K., Xu, X., Lee, J. S., Yoon, H. I., Lee, C. T., Choi, Y. J., Kim, H.-R., Kim, C. H., & Lee, J. C. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.11.011 · Cited by 186

Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition

Miele, L., Espinoza, I. C., Pochampally, Watabe, & Xing, F. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s36162 · Cited by 191

Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options

Yousefi, M., Bahrami, T., Salmaninejad, A., Nosrati, R., Ghaffari, P., & Ghaffari, S. H. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0345-5 · Cited by 180

Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer

Nurwidya, F., Takahashi, F., Murakami, A., & Takahashi, K. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.3.151 · Cited by 177

Epithelial to Mesenchymal Transition by TGFβ-1 Induction Increases Stemness Characteristics in Primary Non Small Cell Lung Cancer Cell Line

Pirozzi, G., Tirino, V., Camerlingo, R., Franco, R., Rocca, A. L., Liguori, E., Martucci, N., Paino, F., Normanno, N., & Rocco, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021548 · Cited by 177

MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells

Cao, M., Seike, M., Soeno, C., Mizutani, H., Kitamura, K., Minegishi, Y., Noro, R., Yoshimura, A., Cai, L., & Gemma, A. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1535 · Cited by 171

Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.

Uramoto, H., Iwata, T., Onitsuka, T., Shimokawa, H., Hanagiri, T., & Oyama, T. (2010) · PubMed · Cited by 168

ERK1/2 Blockade Prevents Epithelial–Mesenchymal Transition in Lung Cancer Cells and Promotes Their Sensitivity to EGFR Inhibition

Buonato, J. M., & Lazzara, M. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4721 · Cited by 163

Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy

Anwar, S., Shamsi, A., Mohammad, T., Islam, A., & Hassan, M. I. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188568 · Cited by 168

Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial–mesenchymal transition of breast cancer cells

Li, Q.-Q., Chen, Z.-Q., Cao, X.-X., Xu, J., Xu, J.-W., Chen, Y.-Y., Wang, W.-J., Chen, Q., Tang, F., Liu, X.-P., et al. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.103 · Cited by 165

Mechanisms of Acquired Resistance to Targeted Cancer Therapies

Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 167

Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Chang, T., Tsai, M.-F., Su, K., Wu, S.-G., Huang, C.-P., Yu, S., Yu, Y., Lan, C., Yang, C.-H., Lin, S.-B., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1440oc · Cited by 162

Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma

Hatakeyama, H., Cheng, H., Wirth, P. S., Counsell, A., Marcrom, S., Wood, C. B., Pohlmann, P. R., Gilbert, J., Murphy, B. A., Yarbrough, W. G., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012702 · Cited by 163

Role of Epidermal Growth Factor Receptor Pathway–Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Cohen, E. E. W. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4577 · Cited by 160

ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors

Huang, C.-P., Tsai, M., Chang, T., Tang, W.-C., Chen, S., Lai, H.-H., Lin, T., Yang, J. C., Yang, P., Shih, J., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.021 · Cited by 162

DNA methylation based biomarkers: Practical considerations and applications

Kit, A. H., Nielsen, H. M., & Tost, J. (2012) · Biochimie · doi:10.1016/j.biochi.2012.07.014 · Cited by 163

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK

Martinelli, E., Morgillo, F., Troiani, T., & Ciardiello, F. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.001 · Cited by 158

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition

Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 169

Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition

Thomson, S., Buck, E. A., Petti, F., Griffin, G., Brown, E., Ramnarine, N., Iwata, K. K., Gibson, N. W., & Haley, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1058 · Cited by 663

Erlotinib sensitivity in NSCLC cell lines correlates with an epithelial to mesenchymal transition which induces a switch in receptor tyrosine kinase signaling.

Thomson, S., Petti, F., Sujka-Kwok, I., Buck, E. A., Barr, S. M., Miglarese, M. R., & Haley, J. D. (2007) · Molecular Cancer Therapeutics

Abstract 5063: Preclinical evaluation of an EMT multi-gene biomarker index for predicting response to inhibitors of EGFR and IGF1R

Argast, G. M., Bean, J. M., Wang, J., O'Connor, M., Feng, B., Nicoletti, R., Lerner, L. R., Heyer, J., Chiu, M. I., Robinson, M. O., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-5063

Epithelial to mesenchymal markers and clinical outcomes on erlotinib in stage IV non-small cell lung cancer patients.

Pool, M. D., Fidler, M. J., Basu, S., Mahon, B., Buckingham, L. E., Walters, K. K., Batus, M., Hensing, T. A., Borgia, J. A., & Bonomi, P. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.e19117

P3-015: Clinicopathologic features and epidermal growth factor receptor mutations associated with epithelial-mesenchymal transition in non-small cell lung cancer

Zhou, C., Deng, Q., & Su, C. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000283501.96516.b4